Theratechnologies Inc. (TSE:TH) had its price target decreased by investment analysts at National Bank Financial from C$9.75 to C$8.75 in a research note issued on Tuesday. The firm currently has an “outperform” rating on the stock. National Bank Financial’s target price would suggest a potential upside of 19.37% from the company’s current price.

Separately, Scotiabank cut their price target on shares of Theratechnologies from C$10.00 to C$9.25 and set an “outperform” rating on the stock in a report on Friday, October 6th.

Shares of Theratechnologies (TH) traded down C$0.17 during trading on Tuesday, hitting C$7.33. 78,814 shares of the stock traded hands, compared to its average volume of 152,934. Theratechnologies has a 1 year low of C$2.61 and a 1 year high of C$8.72.

COPYRIGHT VIOLATION WARNING: This report was originally published by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/11/14/theratechnologies-inc-th-price-target-cut-to-c8-75.html.

Theratechnologies Company Profile

Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.

Receive News & Ratings for Theratechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.